These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33938131)

  • 1. Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease.
    Madrasi K; Das R; Mohmmadabdul H; Lin L; Hyman BT; Lauffenburger DA; Albers MW; Rissman RA; Burke JM; Apgar JF; Wille L; Gruenbaum L; Hua F
    Alzheimers Dement; 2021 Sep; 17(9):1487-1498. PubMed ID: 33938131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease.
    Geerts H; Walker M; Rose R; Bergeler S; van der Graaf PH; Schuck E; Koyama A; Yasuda S; Hussein Z; Reyderman L; Swanson C; Cabal A
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):444-461. PubMed ID: 36632701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.
    Ramakrishnan V; Friedrich C; Witt C; Sheehan R; Pryor M; Atwal JK; Wildsmith K; Kudrycki K; Lee SH; Mazer N; Hofmann C; Fuji RN; Jin JY; Ramanujan S; Dolton M; Quartino A
    CPT Pharmacometrics Syst Pharmacol; 2023 Jan; 12(1):62-73. PubMed ID: 36281062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.
    Geerts H; Spiros A; Roberts P
    Alzheimers Res Ther; 2018 Feb; 10(1):14. PubMed ID: 29394903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?
    Watt AD; Crespi GA; Down RA; Ascher DB; Gunn A; Perez KA; McLean CA; Villemagne VL; Parker MW; Barnham KJ; Miles LA
    Acta Neuropathol; 2014; 127(6):803-10. PubMed ID: 24803227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.
    Bastrup J; Hansen KH; Poulsen TBG; Kastaniegaard K; Asuni AA; Christensen S; Belling D; Helboe L; Stensballe A; Volbracht C
    J Alzheimers Dis; 2021; 79(1):249-265. PubMed ID: 33252074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
    Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
    Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ.
    Meilandt WJ; Maloney JA; Imperio J; Lalehzadeh G; Earr T; Crowell S; Bainbridge TW; Lu Y; Ernst JA; Fuji RN; Atwal JK
    Alzheimers Res Ther; 2019 Dec; 11(1):97. PubMed ID: 31787113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive antiamyloid immunotherapy for Alzheimer's disease.
    Loureiro JC; Pais MV; Stella F; Radanovic M; Teixeira AL; Forlenza OV; de Souza LC
    Curr Opin Psychiatry; 2020 May; 33(3):284-291. PubMed ID: 32040044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.
    Arndt JW; Qian F; Smith BA; Quan C; Kilambi KP; Bush MW; Walz T; Pepinsky RB; Bussière T; Hamann S; Cameron TO; Weinreb PH
    Sci Rep; 2018 Apr; 8(1):6412. PubMed ID: 29686315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.